IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 93.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,045 shares of the company's stock after acquiring an additional 23,230 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd owned approximately 0.08% of Twist Bioscience worth $1,886,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of TWST. First Light Asset Management LLC acquired a new stake in Twist Bioscience during the 4th quarter valued at approximately $56,984,000. Marshall Wace LLP increased its holdings in Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock worth $39,319,000 after acquiring an additional 840,828 shares in the last quarter. ARK Investment Management LLC increased its holdings in Twist Bioscience by 11.5% in the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock worth $245,045,000 after acquiring an additional 645,730 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Twist Bioscience by 86.0% in the fourth quarter. Renaissance Technologies LLC now owns 398,708 shares of the company's stock worth $18,528,000 after buying an additional 184,398 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Twist Bioscience during the 4th quarter worth approximately $7,584,000.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on TWST. JPMorgan Chase & Co. dropped their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. The Goldman Sachs Group dropped their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Guggenheim reissued a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. Barclays dropped their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Finally, Robert W. Baird decreased their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $50.40.
Read Our Latest Stock Analysis on TWST
Insider Transactions at Twist Bioscience
In other news, CEO Emily M. Leproust sold 1,678 shares of the stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.76, for a total transaction of $60,005.28. Following the sale, the chief executive officer owned 645,782 shares of the company's stock, valued at approximately $23,093,164.32. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Laponis sold 2,449 shares of the stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the sale, the chief financial officer directly owned 103,569 shares in the company, valued at $3,951,157.35. This represents a 2.31% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,109 shares of company stock valued at $425,962. 3.01% of the stock is currently owned by corporate insiders.
Twist Bioscience Stock Up 0.3%
Shares of TWST opened at $33.68 on Monday. The stock has a market capitalization of $2.02 billion, a PE ratio of -10.36 and a beta of 2.36. Twist Bioscience Corporation has a 1 year low of $27.12 and a 1 year high of $55.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51. The company's 50-day simple moving average is $34.67 and its 200-day simple moving average is $38.70.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The business had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. Analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.
About Twist Bioscience
(
Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Further Reading
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
